Navigation Links
Delcath Systems Receives Preliminary Notification of Inclusion in Russell 3000(R) Index
Date:6/15/2009

NEW YORK, June 15 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that it will be added to the broad-market Russell 3000(R) Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 26, 2009. According to the preliminary list of additions posted June 12, 2009 on www.russell.com, selection to the Russell 3000(R) Index means Delcath is automatically included in the popular Russell 2000(R) Index, which measures the performance of approximately 2,000 small-cap U.S. securities.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO )

About Russell:

Russell Investments provides strategic advice, world-class implementation, state-of-the-art performance benchmarks and a range of institutional-quality investment products. Russell has $136 billion in assets under management as of March 31, 2009, and serves individual, institutional and advisor clients in more than 40 countries. Founded in 1936, Russell is a subsidiary of The Northwestern Mutual Life Insurance Company.

About Delcath Systems, Inc.:

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Delcath Enters Agreement to Sell 869,565 Units
2. Delcath Systems Granted Third Orphan Drug Designation
3. Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
4. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
5. Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors
6. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
7. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
8. Nanopoint Applies CE Mark to Its cellTRAY(R) Imaging and Microfluidics Systems
9. Penguin Computing Forms OEM Agreement with Applied Biosystems for Scyld ClusterWare
10. SANYO Donates Air Purification Systems Effective Against Flu Viruses to New York Airports and Schools
11. OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016 Despite the ... value in this space. Today,s pre-market research on ActiveWallSt.com directs ... Health Inc. (NASDAQ: RDUS ), Cerus Corp. (NASDAQ: ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... briefings at: http://www.activewallst.com/ On ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Lajollacooks4u has become ... has consistently been rated one of its top attractions. Fortune 500 companies, such ... participate in a unique and intimate team-building experience. , Each event kicks off with ...
(Date:5/25/2016)... Bethesda, Md. (PRWEB) , ... May 25, 2016 ... ... a request for information (RFI) issued by the Office of the National Coordinator ... the patient experience, and determines if clinically relevant data were available when and ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven ... Administration (FDA) has granted the company’s orphan drug designation request covering BHV-4157 for ... designation granted by the FDA. , Spinocerebellar ataxia is a rare, debilitating ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
Breaking Biology News(10 mins):